Image

Structured Peer-delivered ART and Reentry Community Strategy

Structured Peer-delivered ART and Reentry Community Strategy

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The overarching goal of this study is to implement both a transition community adherence club strategy (Group-SPARCS) and an ART provision strategy (ART-SPARCS) for HIV-positive individuals transitioning from correctional to community settings in South Africa. The current proposal will allow for a fully powered effectiveness randomized clinical trial (RCT).

  • To compare the effectiveness of Full-SPARCS, ART-SPARCS, and Group-SPARCS to care as usual and to each other to achieve HIV RNA suppression 6 months following correctional facility release
  • To assess determinants of implementation of Full-SPARCS, ART-SPARCS, and Group-SPARCS.
  • To assess the scalability through costing and cost effectiveness analysis of Full-SPARCS, ART-SPARCS, and Group-SPARCS.

Description

Background: The South African government has devoted resources towards HIV care in correctional facilities that have resulted in antiretroviral therapy (ART) coverage of >90% and viral load (VL) suppression of >80% among incarcerated people living with HIV (PLWH). However, despite free post-release care, the investigators previously observed that only an estimated 34% were in care three months post-release. The investigators developed, tested, and manualized the Structured Peer-delivered ART and Re-entry Community Strategy (SPARCS) to overcome post-incarceration barriers specific to PLWH returning to the community.8-10 In the investigators randomized controlled pilot of SPARCS, 6-month post-release, continuity of care was 61% in the intervention arm compared to 36% in the usual care arm (p=0.001), demonstrating effectiveness. Full-SPARCS, has two distinct components spanning six months post-release: direct provision of ART (ART-SPARCS) and 12 biweekly peer facilitator-led group sessions (Group-SPARCS). ART-SPARCS is designed to overcome clinic-level barriers through bimonthly distribution of ART without a group component. Group-SPARCS is designed to increase self-efficacy, social support, and life skills through facilitated group discussion and curriculum including planning, problem solving, financial literacy, and living with HIV without ART distribution. The current usual care is a supply of ART and a referral letter at the time of release from incarceration.

Methods: This research study will be conducted in Gauteng Province. Recruitment will occur within correctional facilities of the Department of Correctional Services (DCS) - Modderbee, Kgosi Mampuru II, and Johannesburg. All study interventions will occur following release in either Ekurhuleni District, Tshwane District or Johannesburg District. The study population will be comprised of adult (≥18 years old) corrections inmates, either male or female, with known HIV infection and are receiving ART within the correctional facility and are expected to be released back into the community within 3 months of study enrollment Participants will be randomized 1:1:1:1 to either the standard of care, Full-SPARCS, Group-SPARCS, or ART-SPARCS using sequential envelopes with study arm determination sealed inside. Study staff will contact participants to ascertain care status and update contact information at one week, one month, three months, six months, nine months, and twelve months from release. Participants assigned to Group-SPARCS or ART-SPARCS will be asked to attend biweekly sessions. Group-SPARCS activities will include - structured curriculum, symptom screening, and routine laboratory monitoring. ART-SPARCS will include the distribution of pre-packed medication and routine laboratory monitoring. Full-SPARCS includes all components of Group-SPARCS and ART-SPARCS.

Study sample: A total of 640 participants will be randomized to one of the four arms. Sixty of the participants will be selected for participation in qualitative in-depth interviews. An additional 25 staff involved in Transition community adherence club (TCAC) referral, ART provision, implementation, coordination will be enrolled for qualitative in-depth interviews.

Significance: The proposed study is consistent with NIH HIV/AIDS highest priority research and the South African National Strategic Plan on HIV, Tuberculosis (TB), and Sexually Transmitted Infections (STIs) 2017-2022. The research addresses the HIV/AIDS Research Priority of "retention and engagement in these services, and achievement and maintenance of optimal prevention and treatment responses." It also addresses "health disparities" through a focus on recently released inmates, a marginalized population. The proposal also fits with the South African National Strategic Plan prioritizing inmates as a key population for HIV services.

Eligibility

Inclusion Criteria:

  • Incarcerated at one of the participating study enrolment sites, awaiting trial (un-sentenced) and sentenced individuals.
  • Diagnosed with HIV and ART at the time of enrolment.
  • Anticipated release or trial date within three months of study enrolment.
  • Self-report expected to reside in an unrestricted environment within Ekurhuleni, Tshwane, or Johannesburg districts of Gauteng Province and within proximity to one of the SPARCS intervention sites (i.e., within 20km, 45-minute travel time, or two local taxi minibus rides)
  • Willing to participate in study post-release follow-up activities and provide contact information for post-release follow-up.

Exclusion Criteria:

  • <18 years of age.
  • Condition (severe cognitive dysfunction or mental illness) rendering the individual unable to provide informed consent.
  • Unable to provide informed consent to participate in the study.
  • Assessment by DCS health staff indicating that the individual requires a high intensity of care exceeding that which can be provided in a differentiated model of care setting.
  • Not released from the correctional facility during the period of intervention delivery.
  • Release to a region outside of Gauteng.

Study details
    Retention in Care

NCT06027671

Johns Hopkins University

31 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.